{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:20:37Z","timestamp":1793049637157,"version":"4.5.0"},"reference-count":43,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","award":["This study was sponsored by Allergan (prior to its"],"award-info":[{"award-number":["This study was sponsored by Allergan (prior to its"]}],"id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Prim Care Community Health"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Triptans, the most commonly prescribed acute treatments for migraine attacks are, per FDA labeling, contraindicated in cardiovascular (CV) disease patients and have warnings and precautions for those with CV risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Headache specialists, cardiologists, and health economics and outcomes researchers convened to identify diagnostic codes for: (1) CV diseases contraindicating triptans based on FDA labeling; (2) conditions comprising \u201cother significant underlying CV disease\u201d; and (3) CV risk factors included as warnings and precautions for triptans. A retrospective, cross-sectional analysis of commercially insured adult US migraine patients in the 2017 Optum\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Clinformatics\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Data Mart (CDM) and the 2017 IBM\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Watson Health MarketScan\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Commercial Claims database was used to estimate the proportion of migraine patients with CV contraindications and warnings and precautions to triptans.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 56,662 migraine patients analyzed from Optum CDM, 13.5% had \u22651 CV disease as specified in triptan labeling and an additional 8.5% had \u22651 \u201cother CV disease\u201d judged by the panel to constitute a \u201csignificant underlying CV disease\u201d (total: 22.0% migraine patients). Of 176\u2009724 migraine patients analyzed from MarketScan, 12.2% had \u22651 CV disease as specified in the labeling and an additional 8.0% had \u22651 \u201cother significant underlying CV disease\u201d (total: 20.2% of migraine patients). An additional 25.4% and 25.1% of migraine patients had \u22652 CV risk factors in Optum CDM and MarketScan. In total, 47.4% and 45.3% of migraine patients in both databases had a CV disease specified as a contraindication, an \u201cother CV disease\u201d endorsed as significant, or \u22652 CV risk factors identified as warnings and precautions to triptans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Analyses of more than 230,000 people with migraine showed that \u226520% of commercially insured US migraine patients have a CV condition that specifically contraindicates triptan treatment, and an additional 25% have \u22652 CV risk factors identified as warnings and precautions to triptans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2150132720963680","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T09:17:13Z","timestamp":1603444633000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":62,"title":["Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data"],"prefix":"10.1177","volume":"11","author":[{"given":"David W.","family":"Dodick","sequence":"first","affiliation":[{"name":"Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3138-5623","authenticated-orcid":false,"given":"Anand S.","family":"Shewale","sequence":"additional","affiliation":[{"name":"AbbVie, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, NY, USA"},{"name":"Montefiore Headache Center, Bronx, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth J.","family":"Baum","sequence":"additional","affiliation":[{"name":"Preventive Cardiology, Boca Raton, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Marcus","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-5567","authenticated-orcid":false,"given":"Stephen D.","family":"Silberstein","sequence":"additional","affiliation":[{"name":"Jefferson Headache Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena M.","family":"Pavlovic","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, NY, USA"},{"name":"Montefiore Headache Center, Bronx, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan L.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Preferred Healthcare Partners, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Young","sequence":"additional","affiliation":[{"name":"Jefferson Headache Center, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema N.","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"AbbVie, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalpa A.","family":"Doshi","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Weintraub","sequence":"additional","affiliation":[{"name":"NYU Langone Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"bibr1-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr2-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"bibr3-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"bibr4-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1111\/head.12878"},{"key":"bibr5-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.02.013"},{"key":"bibr6-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0946-z"},{"key":"bibr7-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32335-3"},{"key":"bibr8-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.6.754"},{"key":"bibr9-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"bibr10-2150132720963680","unstructured":"How gepants and ditans complement existing therapies. 2020. Available at: https:\/\/americanmigrainefoundation.org\/resource-library\/gepants-ditans-therapies\/#:~:text=When%20a%20patient%20is%20dissatisfied,risk%20of%20medication%20overuse%20headache. Accessed: June 11, 2020."},{"key":"bibr11-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1111\/head.13275"},{"key":"bibr12-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1111\/head.12198"},{"key":"bibr13-2150132720963680","first-page":"68","volume":"58","author":"Alam A","year":"2018","journal-title":"Headache"},{"key":"bibr14-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.12.020"},{"key":"bibr15-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.11.025"},{"key":"bibr16-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2015"},{"key":"bibr17-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181a71220"},{"key":"bibr18-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k96"},{"key":"bibr19-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003428"},{"key":"bibr20-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.12.021"},{"key":"bibr21-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6635"},{"key":"bibr22-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7172"},{"key":"bibr23-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318254"},{"key":"bibr24-2150132720963680","unstructured":"Zomig ZMT [package insert]. Bridgewater, NJ: Amneal Specialty; 2019."},{"key":"bibr25-2150132720963680","unstructured":"Relpax [package insert]. New York, NY: Roerig, Division of Pfizer Inc.; 2013."},{"key":"bibr26-2150132720963680","unstructured":"Maxalt [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2019."},{"key":"bibr27-2150132720963680","unstructured":"Imitrex [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2017."},{"key":"bibr28-2150132720963680","unstructured":"Frova [package insert]. Malvern, PA: Endo Pharmaceuticals, Inc; 2018."},{"key":"bibr29-2150132720963680","unstructured":"Axert [package inset]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2017."},{"key":"bibr30-2150132720963680","unstructured":"Amerge [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2016."},{"issue":"11","key":"bibr31-2150132720963680","first-page":"e596","volume":"140","author":"Arnett DK","year":"2019","journal-title":"Circulation"},{"key":"bibr32-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199801000-00004"},{"key":"bibr33-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1111\/head.12962"},{"key":"bibr34-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d0cc8b"},{"key":"bibr35-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1111\/head.13179"},{"key":"bibr36-2150132720963680","unstructured":"Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory. Accessed: February 18, 2020."},{"key":"bibr37-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009324"},{"key":"bibr38-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1111\/head.12499"},{"key":"bibr39-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1111\/head.12870"},{"key":"bibr40-2150132720963680","unstructured":"Ubrelvy [package insert]. Madison, NJ: Allergan USA, Inc.; 2020."},{"key":"bibr41-2150132720963680","unstructured":"Reyvow [package insert]. Indianapolis, IN: Lilly USA; 2020."},{"key":"bibr42-2150132720963680","unstructured":"Nurtec ODT [package insert]. New Haven, CT: Biohaven Pharmaceuticals, Inc.; 2020."},{"key":"bibr43-2150132720963680","doi-asserted-by":"publisher","DOI":"10.1111\/head.13281"}],"container-title":["Journal of Primary Care &amp; Community Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2150132720963680","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2150132720963680","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2150132720963680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:25:04Z","timestamp":1777508704000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2150132720963680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":43,"alternative-id":["10.1177\/2150132720963680"],"URL":"https:\/\/doi.org\/10.1177\/2150132720963680","relation":{},"ISSN":["2150-1319","2150-1327"],"issn-type":[{"value":"2150-1319","type":"print"},{"value":"2150-1327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"2150132720963680"}}